BioXcel Therapeutics Inc (BTAI) Stock Analysis
Verdict: AVOID
Extreme liquidity distress and -$95.5M negative equity make dilution or restructuring imminent despite IGALMI commercial status.
Investment score: 10/100
Analysis as of
Is BioXcel Therapeutics Inc stock worth reviewing? AI model thesis
The AI model views BioXcel Therapeutics as a high-risk microcap facing insolvency. With $109.66M in debt, -$95.46M in equity, and an annual cash burn of -$57.62M against $28.42M in cash at year-end 2025, the risk of massive dilution or Chapter 11 restructuring is critical.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 25/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
BioXcel Therapeutics Inc opportunities and risks
What speaks for BTAI
- Potential expansion of IGALMI or pipeline asset BXCL501 into Phase 3 Alzheimer's agitation trials
What speaks against BTAI
- Imminent cash exhaustion and severe cash burn rate relative to cash reserves
Frequently asked questions about BioXcel Therapeutics Inc (BTAI)
Is BTAI stock a good investment?
The cached TradeMates AI model rates BioXcel Therapeutics Inc as AVOID with an investment score of 10/100. The AI model views BioXcel Therapeutics as a high-risk microcap facing insolvency. With $109.66M in debt, -$95.46M in equity, and an annual cash burn of -$57.62M against $28.42M in cash at year-end 2025, the risk of massive dilution or Chapter 11 restructuring is critical. This is algorithmic model output, not personal investment advice.
Is BTAI stock a buy?
The TradeMates model verdict for BTAI is AVOID with an investment score of 10/100. Treat this as a model signal to review, not a personal buy recommendation.